A Phase 1b, Multicenter, Open Label Study Evaluating Safety, Tolerability and Preliminary Efficacy of GemRIS 225 mg in Subjects With Non-Muscle-Invasive Urothelial Carcinoma of the Bladder
Phase of Trial: Phase I
Latest Information Update: 24 Oct 2016
At a glance
- Drugs Gemcitabine (Primary)
- Indications Bladder cancer
- Focus Adverse reactions
- Sponsors TARIS Biomedical
- 10 Jun 2017 Biomarkers information updated
- 02 Aug 2016 Status changed from not yet recruiting to recruiting.
- 12 Jul 2016 Planned primary completion date changed from 1 Jan 2017 to 1 Dec 2016.